HTX 0.00% 0.1¢ healthlinx limited

another article from yesterday: Home News New Hope to Women Co.....

  1. 1,574 Posts.
    lightbulb Created with Sketch. 20
    another article from yesterday:

    Home News New Hope to Women Co.. 24-02-2010 - 07:00New Hope to Women Concerned About Ovarian Cancer
    LONDON, February 24, 2010 /PRNewswire/ -- A simple blood test that could help save lives by detecting ovarian

    cancer at an earlier stage is available in the UK from 25 February 2010.

    Called OvPlex(TM), the test is being welcomed by cancer specialists and

    ovarian cancer charities as a superior performing diagnostic for the earlier

    detection of ovarian cancer in symptomatic women.



    OvPlex(TM) is being introduced into the UK by Intus Healthcare, having

    secured distribution rights from the Australian ASX listed company that

    developed the test, HealthLinx Ltd.



    Spire Healthcare is supporting the UK launch, with women attending its

    hospitals to have the blood test performed. Designed for symptomatic women or

    those with a family history of ovarian cancer, the OvPlex(TM) test is ordered

    directly from Intus Healthcare (http://www.ovplex.co.uk). A test wallet with

    details of the local Spire hospital will be sent to the patient by post and

    the results are then sent to the patient's GP to discuss with the patient.



    Some 6,600 British women are diagnosed with ovarian cancer each year and

    diagnosis often comes too late as only 40% of those diagnosed live beyond

    five years[i].



    Malcolm Padwick, specialist gynaecological surgeon at Spire Bushey

    Hospital and lead gynaecological oncology surgeon for West Hertfordshire

    Hospitals NHS Trust, explains: "Ovarian cancer is the most fatal

    gynaecological cancer because women are often not diagnosed until the late

    stage of the disease. To provide early stage diagnostic tests makes a real

    difference to outcomes."



    OvPlex(TM), launched Australia in 2008, is a superior alternative to

    other available diagnostic tests, including CA125, and measures the increased

    levels of five proteins in the blood. Results of a phase 2 biomarker study in

    2008 reported 94% accuracy in diagnosing ovarian cancer, compared to 89% for

    CA125 alone.



    Nick Gatsios, MD of HealthLinx Ltd comments: "We are confident of the

    benefits OvPlex(TM) offers symptomatic women as it is by far the most

    effective diagnostic for the detection of ovarian cancer at all stages."



    Louise Bayne, CEO of Ovacome, a charity dedicated to helping women and

    families suffering from the disease comments: "OvPlex(TM) is an exciting

    development offering hope for women seeking a better chance of either

    alleviating their concerns or getting an early diagnosis. The trial data on

    OvPlex(TM) indicates excellent potential."

    cheers!
 
watchlist Created with Sketch. Add HTX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.